The Respiratory Syncytial Virus (RSV) vaccine called AREXVY has been approved for use in Australia. Produced by GlaxoSmithKline, it is the first vaccine developed for the prevention of lower respiratory tract disease caused by RSV in individuals aged 60 and over, and has been approved by The Therapeutic Goods Administration (TGA). AREXVY has already received approval for use in several countries, including the UK, the European Union, the US, Canada, and Japan.